Zatik Med Kft.
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zatik, Janos
NCT04209543 / 2019-001289-14: Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Completed
3
1570
Europe, Canada, US, RoW
Estetrol, Placebo, Progesterone
Estetra, ICON Clinical Research
Vasomotor Symptoms, Menopausal Symptoms
02/24
02/24
NCT06211049: Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

Active, not recruiting
3
286
Europe, RoW
Vitex agnus-castus BNO 1095 (20 mg), Placebo
Bionorica SE, FGK Clinical Research GmbH
Primary Dysmenorrhea
03/25
03/25
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Completed
2
354
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25
Nyirady, Tamas
NCT06211049: Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

Active, not recruiting
3
286
Europe, RoW
Vitex agnus-castus BNO 1095 (20 mg), Placebo
Bionorica SE, FGK Clinical Research GmbH
Primary Dysmenorrhea
03/25
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zatik, Janos
NCT04209543 / 2019-001289-14: Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Completed
3
1570
Europe, Canada, US, RoW
Estetrol, Placebo, Progesterone
Estetra, ICON Clinical Research
Vasomotor Symptoms, Menopausal Symptoms
02/24
02/24
NCT06211049: Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

Active, not recruiting
3
286
Europe, RoW
Vitex agnus-castus BNO 1095 (20 mg), Placebo
Bionorica SE, FGK Clinical Research GmbH
Primary Dysmenorrhea
03/25
03/25
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Completed
2
354
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25
Nyirady, Tamas
NCT06211049: Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

Active, not recruiting
3
286
Europe, RoW
Vitex agnus-castus BNO 1095 (20 mg), Placebo
Bionorica SE, FGK Clinical Research GmbH
Primary Dysmenorrhea
03/25
03/25

Download Options